Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?
- 23 June 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in NeuroMolecular Medicine
- Vol. 12 (4), 331-340
- https://doi.org/10.1007/s12017-010-8121-y
Abstract
The public health burden of Alzheimer disease (AD), the most common neurodegenerative disease, threatens to explode in the middle of this century. Current FDA-approved AD treatments (e.g. cholinesterase inhibitors, NMDA-receptor agonists) do not provide a “cure”, but rather a transient alleviation of symptoms for some individuals. Other available therapies are few and of limited effectiveness so additional avenues are needed. Sphingolipid metabolism is a dynamic process that modulates the formation of a number of bioactive metabolites, or second messengers critical in cellular signaling and apoptosis. In brain, the proper balance of sphingolipids is essential for normal neuronal function, as evidenced by a number of severe brain disorders that are the result of deficiencies in enzymes that control sphingolipid metabolism. Laboratory and animals studies suggest both direct and indirect mechanisms by which sphingolipids contribute to amyloid-beta production and Alzheimer pathogenesis but few studies have translated these findings to humans. Building on the laboratory and animal evidence demonstrating the importance of sphingolipid metabolism in AD, this review highlights relevant translational research incorporating and expanding basic findings to humans. A brief biological overview of sphingolipids (sphingomyelins, ceramides, and sulfatides) in AD is first described, followed by a review of human studies including post-mortem studies, clinical and epidemiological studies. Lastly, the potential role of peripheral ceramides in AD pathogenesis is discussed, as well as the possible use of sphingolipids as biomarkers for AD.Keywords
This publication has 65 references indexed in Scilit:
- Deregulation of sphingolipid metabolism in Alzheimer's diseaseNeurobiology of Aging, 2010
- Serum sphingomyelins and ceramides are early predictors of memory impairmentNeurobiology of Aging, 2010
- ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brainNeurobiology of Aging, 2009
- Thematic Review Series: Sphingolipids. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease—a reviewJournal of Lipid Research, 2008
- Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapiesInternational Psychogeriatrics, 2008
- Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid MetabolismEndocrine Reviews, 2008
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2006
- Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathwayThe Journal of cell biology, 2004
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982